Resultados de la búsqueda 11-20 of 1498 for SC

  1. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

  2. Anafilaxia - Médicos y departamentos - Mayo Clinic

    Mostrando 1-10 de doctores disponibles · Fernanda Bellolio, M.D., M.S. · Kimberly G. Blumenthal, M.D., M.Sc. · Kate M. Freeman, M.B., B.Ch. · John B. Hagan, M.D..

  3. Nefrología e hipertensión - Ensayos clínicos

    Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  5. Nefrología e hipertensión - Ensayos clínicos

    Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  7. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  8. Oncología (médica) - Ensayos clínicos

    Also, to evaluate safety and tolerability and determine RP2D of YH001 in combination with envafolimab dosed at 600 mg SC every 3 weeks and doxorubicin dosed at ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  10. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...